skip to main content

Recalcitrant Incomplete Secukinumab Administration in a Psoriasis Patient

1Faculty of Medicine, Universitas HKBP Nommensen, Indonesia

2Faculty of Medicine, Dentistry, and Health Sciences, Universitas Prima Indonesia, Indonesia

Received: 29 Jul 2023; Revised: 22 Oct 2023; Accepted: 7 Dec 2023; Available online: 31 Dec 2023; Published: 31 Dec 2023.
Open Access Copyright (c) 2023 Journal of Biomedicine and Translational Research
Creative Commons License This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Citation Format:

Background: Psoriasis is an immunologic-mediated disease affected by genetic factors that may affect the skin, joints, and cardiovascular system. Some biological agents have been developed and approved by FDA to treat psoriasis. One of these biological agents is Secukinumab, a fully human IgG1κ anti-interleukin-17A(IL-17A) monoclonal antibody.

Case Presentation: A seventeen female teenager came to Dermatovenerology Clinic with scaly patches in the forehead and hairline around ten months ago with a history of repeat Corticoticosteroid, DMARDs, and biologic agent treatment. Dermatology examination showed erythema, induration, and desquamation in head and extremities with PASI score of 1.2. She was treated with initial and maintenance doses of Secukinumab Injection.

Conclusion: It can be concluded that the recalcitrant administration of Secukinumab in Psoriasis patients may decrease the treatment response.

Note: This article has supplementary file(s).

Fulltext View|Download |  Cover Letter
Covering letter
Type Cover Letter
  Download (140KB)    Indexing metadata
Copyright Transfer Agreement
Type Other
  Download (186KB)    Indexing metadata
Keywords: Psoriasis; Secukinumab; Recalcitrant; PASI; IL17A

Article Metrics:

  1. Jacoeb TNA. Psoriasis. In: Menaldi SLS, Bramono K, Indriatmi W, editors. Ilmu Penyakit Kulit dan Kelamin. Ketujuh. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia; 2015. p. 213–22
  2. Gudjonsson JE, Elder JT. Psoriasis. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al., editors. Fitzpatrick’s Dermatology. 9th ed. New York: McGraw Hill; 2019. p. 457–97
  3. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol [Internet]. 2013;133(2):377–85. Available from:
  4. Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front Immunol. 2022;13(June):1–19
  5. Piragine E, Petri D, Martelli A, Janowska A, Dini V, Romanelli M, et al. Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis. J Clin Med. 2022;11(6)
  6. Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia (PERDOSKI). Panduan Praktik Klinis Bagi Dokter Spesialis Kulit dan Kelamin di Indonesia. Widaty S, Soebono H, Nilasari H, Listiawan MY, Siswati AS, Triwahyudi D, et al., editors. Jakarta: Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia (PERDOSKI); 2017. 230–240 p
  7. Huang Y-H, Tang C-H, Goh CH, Chang C-L, Qiu H, Yang Y-W, et al. Persistence and Adherence to Biologics in Patients with Psoriasis in Taiwan: A New Biologics User Cohort Study. Front Pharmacol. 2022;13(May):1–9
  8. Lake DF, Briggs AD, Akporiaye ET. Immunopharmacology. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic & Clinical Pharmacology. 12th ed. New York: Mc Graw Hill Lange; 2012. p. 977–1000
  9. Berman J, Furer V, Berman M, Isakov O, Zisman D, Haddad A, et al. Treatment with ixekizumab following secukinumab failure in patients with psoriatic arthritis: Real-life experience from a resistant population. Biol Targets Ther. 2021;15:463–70
  10. Deodhar A, Gladman DD, McInnes IB, Spindeldreher S, Martin R, Pricop L, et al. Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis. J Rheumatol. 2020;47(4):539–47
  11. Reich K, Blauvelt A, Armstrong A, Langley RG, de Vera A, Kolbinger F, et al. Secukinumab, a Fully Human Anti-Interleukin-17A Monoclonal Antibody, Exhibits Low Immunogenicity in Psoriasis Patients Treated Up to 5 Years. J Eur Acad Dermatology Venereol. 2019;33(9):1733–41
  12. Amschler K, Phillip S, Mohr J, Wilsmann-Theis D, Poortinga S, Gerdes S, et al. Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab. Dermatol Online J. 2020;26(1):1–5

Last update:

No citation recorded.

Last update:

No citation recorded.